Amgen claims osteoporosis drug tops rival in study (AP via Yahoo! Finance)

Biotechnology company Amgen Inc. said Monday its developing osteoporosis treatment denosumab was more effective than Merck & Co.’s rival drug Fosamax in a late-stage study.

This entry was posted on Tuesday, May 20th, 2008 at 11:34 pm and is filed under Osteoporosis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.